Life Science Investing Corvus Pharmaceuticals Announces Presentation of Interim Data from the Phase 1b/2 Clinical Trial of Ciforadenant for Patients with Metastatic Renal Cell Cancer at the European Society for Medical Oncology Congress 2025
pharmaceutical investing Corvus Presents Updated Biomarker and Clinical Results from Lead Pipeline Programs
Corvus Announces Presentation of Preclinical Data on CPI-818, a First-in-class Covalent Inhibitor of ITK Targeting T-Cell Lymphomas
pharmaceutical investing Corvus Pharmaceuticals Announces Initiation of Phase 1/1b Clinical Trial of Investigational Anti-CD73 Antibody, CPI-006
pharmaceutical investing Corvus Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results
Corvus Pharmaceuticals to Present Data on Lead Oral Checkpoint Inhibitor CPI-444 at Second CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference
Torchlight Innovations (Doing Business as RZOLV Technologies) Announces Preliminary Positive Results on Rare Earth and Critical Mineral Recoveries
